Neurogenesis-Independent Antidepressant-Like Effects on Behavior and Stress Axis Response of a Dual Orexin Receptor Antagonist in a Rodent Model of Depression

Mathieu Nollet¹, Philippe Gaillard^{1,2}, Arnaud Tanti¹, Virginie Girault¹, Catherine Belzung¹ and Samuel Leman^{*,1}

¹Inserm U930—Imaging and Brain, Université François Rabelais, UFR Sciences et Techniques, Tours, France; ²Clinique Psychiatrique Universitaire, CHRU de Tours, Tours, France

Growing evidence indicates that an increase of orexin (or hypocretin) signaling is involved in the pathophysiology of major depression, but little is known regarding the causal link between the orexinergic system and depressive-like states. Here we blocked orexin receptors in mice subjected to unpredictable chronic mild stress (UCMS) to investigate putative antidepressant-like effects of this treatment, as well as the underlying mechanisms. BALB/c mice were exposed to 9 weeks of UCMS and from the third week onward treated daily with fluoxetine (20 mg/kg per day, *per os*) or with the dual orexin receptor antagonist almorexant (100 mg/kg per day, *per os*). The effects of UCMS regimen and pharmacological treatments were assessed by physical measures and behavioral testing. The dexamethasone suppression test was performed to examine the integrity of the negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis, and immunohistochemical markers were used to assess cell proliferation (Ki-67), immature newborn neurons (doublecortin), and mature newborn neurons (5-bromo-2'-deoxyuridine/NeuN) in the dorsal and ventral parts of the hippocampus. Our results show that 7 weeks of fluoxetine or almorexant treatments counteract the UCMS-induced physical and behavioral alterations. Both treatments prevented the HPA axis dysregulation caused by UCMS, but only fluoxetine reversed the UCMS-induced decrease of hippocampal cell proliferation and neurogenesis, while chronic almorexant treatment decreased cell proliferation and neurogenesis specifically in the ventral hippocampus. Taken together, this is the first evidence that pharmacological blockade of the orexinergic system induces a robust antidepressant-like effect and the restoration of stress-related HPA axis defect independently from a neurogenic action.

Neuropsychopharmacology (2012) **37**, 2210–2221; doi:10.1038/npp.2012.70; published online 20 June 2012

Keywords: depression; orexin/hypocretin; antidepressant; dual orexin/hypocretin receptor antagonist; hippocampal neurogenesis; hypothalamic-pituitary-adrenal axis

INTRODUCTION

Major depression (MD), a pathology that can be triggered by chronic psychosocial stress in vulnerable subjects (El Hage *et al*, 2009; Keller *et al*, 2007), is characterized by mood disturbance, anhedonia, sleep abnormalities, weight changes, and dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis (Nestler *et al*, 2002; Tanti and Belzung, 2010). Recently, adult hippocampal neurogenesis has been suggested either to participate in the etiology of MD (Snyder *et al*, 2011) or to be causally involved in the ability of antidepressant drugs to elicit a therapeutic response (Airan

et al, 2007; David *et al*, 2009; Jiang *et al*, 2005; Perera *et al*, 2011; Santarelli *et al*, 2003; Surget *et al*, 2008; Wang *et al*, 2008). Traditional antidepressants (e.g., selective serotonin reuptake inhibitors (SSRIs)) and novel drugs that exert antidepressant-like effects (e.g., antagonists at metabotropic glutamate receptors, synthetic cannabinoid HU210, tianeptine, compounds acting on the stress axis such as corticotropin-releasing hormone 1 (CRH1) or vasopressin V1b receptor antagonists, or melanin-concentrating hormone (MCH) antagonist) both appear to increase hippocampal neurogenesis despite their different pharmacological mechanisms (Alonso *et al*, 2004; Czéh *et al*, 2001; David *et al*, 2007; Jiang *et al*, 2005; McEwen *et al*, 2002; Yoshimizu and Chaki 2004). This was also observed with non-pharmacological therapy, such as electroconvulsive therapy (Malberg *et al*, 2000) or vagus nerve stimulation (Revesz *et al*, 2008). We have recently shown that this occurs via the potential of antidepressants to recruit new hippocampal neurons to rescue the HPA axis regulation defects (Surget *et al*, 2011),

*Correspondence: Dr S Leman, UMR Inserm 930—Imaging and Brain, Team 4: Affective Disorders, Université François Rabelais, UFR Sciences et Techniques, Parc Grandmont, 37200 Tours, France, Tel: +33 02 47 36 69 97, Fax: +33 02 47 36 72 85, E-mail: samuel.leman@univ-tours.fr

Received 30 January 2012; revised 16 March 2012; accepted 2 April 2012

suggesting that restoration of the HPA axis feedback is sufficient to induce therapeutic effects, even in a context in which a given treatment does not stimulate hippocampal neurogenesis.

Orexins, also known as hypocretins, are a pair of excitatory neuropeptides called orexin-A (OX-A) and orexin-B (OX-B) (hypocretin-1 and hypocretin-2), synthesized from the common precursor prepro-orexin (de Lecea *et al*, 1998; Sakurai *et al*, 1998). They are produced by a population of neurons located in the dorsomedial hypothalamus (DMH), perifornical hypothalamic area (PFA), and lateral hypothalamus (LH), from which they send projections broadly all over the brain (Peyron *et al*, 1998). Physiological effects of orexins result from the activation of two G-protein-coupled receptors differentially distributed throughout the brain (Marcus *et al*, 2001; Trivedi *et al*, 1998), orexin receptor 1 and 2 (OXR1 and OXR2), with OX-A showing equal affinity for both receptors, while OX-B demonstrates a higher affinity for OXR2 (Sakurai *et al*, 1998).

Interestingly, orexins are implicated in several processes that are dysregulated in depressive subjects, including sleep/wake transitioning (Cao and Guilleminault, 2011; Sakurai *et al*, 2010), control of food intake (Cason *et al*, 2010; Thompson and Borgland, 2011), reward seeking (Aston-Jones *et al*, 2010; Harris *et al*, 2005), and HPA axis regulation (Lopez *et al*, 2010; Spinazzi *et al*, 2006), suggesting that orexins could be partly involved in the pathophysiology of MD. Nonetheless, preclinical and clinical studies that investigated the link between orexinergic system and MD still report conflicting results, showing that either hypoactivity (Allard *et al*, 2004; Brundin *et al*, 2007a; Ito *et al*, 2008; Lutter *et al*, 2008; Rotter *et al*, 2011) or hyperactivity (Feng *et al*, 2008; Mikrouli *et al*, 2011; Nollet *et al*, 2011; Salomon *et al*, 2003; von der Goltz *et al*, 2011) of the orexinergic system is associated with depressive state.

To further study the exact role of orexins in depressive-like states, we exposed mice to the unpredictable chronic mild stress (UCMS), a widely used naturalistic animal model of MD (Cryan and Holmes, 2005; Sibille *et al*, 2009; Surget *et al*, 2009; Willner, 1997). We then studied the behavioral and neurobiological effects of a chronic

treatment with the dual orexin receptor antagonist almorexant (ALM) (Brisbare-Roch *et al*, 2007), compared to the classical antidepressant fluoxetine (FLX), a selective serotonin reuptake inhibitor (SSRI), with an emphasis on adult hippocampal neurogenesis and HPA stress axis. Here, we demonstrate that behavioral disturbances induced by chronic stress exposure are reversed by the dual orexin receptor antagonist, which counteracted HPA axis dysregulation through a neurogenesis-independent mechanism.

MATERIALS AND METHODS

Animals

In all, 95 BALB/c mice (Centre d'élevage Janvier, Le Genest St-Isle, France), aged between 6 and 7 weeks at the time of their arrival in the laboratory, were housed in groups of four per cage under standard conditions ($22 \pm 2^\circ\text{C}$, 40% humidity, inverted 12-h light-dark cycle with lights off at 0900 h, food and water *ad libitum*) for 1 week before the beginning of experimental procedures. All experimental procedures were carried out in strict accordance with the European Communities Council directive (86/609/EEC) and received the approval of the ethical committee (agreement no. 2011-06-10, Comité d'Ethique en Expérimentation Animale Val de Loire, CEEAVdL).

Experimental Design

UCMS regimen used in this study has been previously presented in detail (Nollet *et al*, 2011) and is a variant of chronic mild stress procedures described by Willner (1997) in rats. Briefly, mice were subjected daily to various socio-environmental low-intensity stressors according to an unpredictable schedule for a total period of 9 weeks (Figure 1). Pharmacological treatment started 2 weeks after the beginning of the UCMS protocol, and was always maintained until the end of the experiment. Body weight and coat state (high score indicates a coat in poor condition) were assessed weekly as markers of the progression of the UCMS-evoked syndrome. Behavioral

Figure 1 Schematic representation of the experimental design. Half of the mice were subjected to a 9-week unpredictable chronic mild stress (UCMS mice), whereas the others served as control (non-UCMS mice). After 2 weeks of UCMS, each group received daily administration of vehicle (VEH, Methocel, 10 ml/kg per day), fluoxetine (FLX, 20 mg/kg per day), or almorexant (ALM, 100 mg/kg per day) *per os* (p.o.) until the end of the experiment. The coat state and the body weight were assessed weekly by an experimenter blind to the treatment. On the ninth week, behavioral tests (actimeter, elevated plus maze, resident-intruder test, tail suspension test and novelty-suppressed feeding test) were carried out. At the end of the UCMS regimen, mice were exposed to the dexamethasone (DEX) suppression test, followed by acute stress (forced swim) before blood and brain collection for radioimmunoassay and immunohistochemical analyses, respectively.

tests were performed in week 8 ($n = 14$ – 19 mice per group), at least 18 h after the last treatment (all mice were subjected to one test daily, always in the same sequence). To label newborn adult cells in the dentate gyrus (DG) of the hippocampus, the thymidine analogous 5-bromo-2'-deoxyuridine (BrdU, B5002; Sigma-Aldrich) was injected intraperitoneally 4 weeks before intracardiac perfusions (4 injections of 75 mg/kg every 2 h, during 2 days). At the end of the UCMS protocol, all mice were subjected to dexamethasone (DEX) suppression test 2 h before being perfused. For further details, see Supplementary Materials and Methods.

Drugs

The SSRI FLX-HCl (Sequoia Research Products, Pangbourne, UK) and the dual orexin receptor antagonist ALM (ACT-078573-hydrochloride; Actelion Pharmaceuticals, Basel, Switzerland) were dissolved in 0.2% methylcellulose (Methocel, 64620; Sigma-Aldrich) water solution. Non-UCMS and UCMS mice daily received *per os* (10 ml/kg per day) freshly prepared vehicle (VEH, 0.2% methylcellulose), FLX (20 mg/kg per day), or ALM (100 mg/kg per day). The selected dose for chronic ALM administration was based on previous experiment (Kang *et al*, 2009). Oral drug administrations were made between 1300 and 1500 h, irrespective of the stress schedule.

Behavioral Testing

A brief description of the behavioral tests is presented here. For a full and detailed description, please refer to Supplementary Materials and Methods.

Basal locomotor activity. An actimeter was used 2 h (afternoon, ie, during the dark phase of the cycle), 10 h (night, ie, during the light phase of the cycle), and 18 h (morning, ie, at the beginning of the dark phase) after drug administration to assess the long-lasting effects of UCMS and pharmacological treatments on basal locomotor activity of mice in their home cage. Locomotor activity was measured during 2 h for each time point.

Elevated plus maze. The elevated plus maze (EPM) consists in a plus-cross-shaped maze, elevated from the floor, with two opposite enclosed arms and two others opened and brightly lit. Mice were placed in the center area facing one of the closed arms and their movements and time spent in the different arms were analyzed for 5 min. The time spent in the open arms is associated with a reduction of anxiety behavior.

Resident-intruder test. The resident-intruder (R-I) test was performed as described previously (Nollet *et al*, 2011) and allows to measure the agonistic behavior of mice. The latency of the first attack and the number of attack(s) (data not shown) were measured over a 6-min period. Depressive-like animals are more agonistic and likely to attack more often and sooner than non-stressed animals (Mineur *et al*, 2003).

Tail suspension test. As described previously (Steru *et al*, 1985), mice were suspended by the tail using adhesive tape to a rod 60 cm above the floor. The trials were conducted for

a period of 6 min and were video recorded. The behavioral measure was the duration of immobility, interpreted as behavioral despair.

Novelty-suppressed feeding test. The novelty-suppressed feeding (NSF) test used in this study has been described formerly (Surget *et al*, 2008). Fasted mice were placed in a corner of a square arena where a single pellet of food was placed on a white paper positioned in the box center. The latency to chew the pellet was recorded within a 3-min period. This test induces a conflicting motivation between the drive to eat the food pellet and the fear of venturing into the arena.

DEX Suppression Test

To assess the effects of UCMS and treatments on the HPA axis negative feedback, the glucocorticoid receptor agonist DEX-phosphate (D-1759; Sigma-Aldrich) was used to carry out a DEX suppression test. For this purpose, all mice were intraperitoneally injected with either DEX (0.1 mg/kg in 0.9% NaCl, $n = 5$ mice per group) or saline (0.9% NaCl, $n = 5$ mice per group). After 30 min, mice were subjected to an acute stressor (forced swim) for 6 min to challenge the HPA axis in the same manner for all experimental groups whether they were chronically stressed or not. Then, 90 min later (ie, 120 min after DEX injection), mice were deeply anesthetized with sodium pentobarbital (40 mg/kg, intraperitoneally), transcardially perfused, and their brains were collected for immunohistochemical analyses of Fos expression in the paraventricular nucleus (PVN). Blood was also collected for plasma corticosterone level analyses. Plasma was separated and stored at -20°C until radioimmunoassay.

Quantification of Corticosterone Levels

Plasma was analyzed for total corticosterone levels using a ^{125}I -labeled corticosterone double-antibody radioimmunoassay kit (MP Biomedicals, New York, NY) according to the manufacturer's protocol. To avoid inter-assay variability, all the samples were run in a single assay. Percentages of plasma corticosterone level's suppression induced by DEX injection were calculated taking the mean level of plasma corticosterone in animals of corresponding group injected with saline solution.

Immunohistochemistry

Immunohistochemical staining was performed to assess the neuronal activity (c-Fos protein) within the PVN of the hypothalamus (to assess the activity of this nucleus known to initiate the HPA axis cascade), the cell proliferation (Ki-67 protein), and the neurogenesis (immature newborn neurons with doublecortin (DCX) staining and mature new neurons with BrdU + NeuN double staining) in the DG of hippocampus (Supplementary Figure 1; full immunohistochemical details are provided in Supplementary Materials and Methods).

Image Analyses and Cell Quantification

Activity of hypothalamic nuclei related to HPA axis activity was assessed by the analysis of Fos-labeled neurons in the parvocellular nuclei of the PVN whose axons are known to

release the CRH. The nomenclature and nuclei boundaries used were those defined by Franklin and Paxinos's (2008) mouse brain atlas. Hippocampal cell proliferation and neurogenesis were assessed by the analysis of Ki-67-labeled (cell proliferation), DCX-labeled (newborn immature neu-

Figure 2 Effects of the unpredictable chronic mild stress (UCMS) and of 7-week treatment with fluoxetine (FLX, 20 mg/kg per day, *per os* (p.o.)) or almorexant (ALM, 100 mg/kg per day, p.o.) on the coat state, body weight and locomotor activity. (a) UCMS induced a significant deterioration of the coat state, as demonstrated by increasing coat state scores, from the week 1 until the end of the UCMS protocol (non-UCMS/vehicle (VEH) group vs *UCMS/VEH group). Drug treatments initiated in the beginning of the third week of the UCMS exposure reversed this deterioration after 3 weeks of treatment (UCMS/VEH group vs §UCMS/FLX or §UCMS/ALM groups). No significant difference was observed between the non-UCMS groups. (b) A gradual increase of body weight was observed during the 9 weeks of UCMS without effects of chronic stress or FLX treatment, but with significant differences at the end of the experiment. ALM-treated mice presented slower weight gain in both non-UCMS mice (non-UCMS/ALM group vs §non-UCMS/VEH or §non-UCMS/FLX groups) and UCMS mice (UCMS/ALM group vs #UCMS/VEH or #UCMS/FLX groups). (c) ALM induced a decrease of locomotor activity only 2 h after administration in non-UCMS mice (non-UCMS/ALM group vs §non-UCMS/VEH or §non-UCMS/FLX groups) and in UCMS mice (UCMS/ALM group vs #UCMS/VEH or #UCMS/FLX groups). In addition, this ALM-induced decrease of locomotor activity was greater in unstressed animals (non-UCMS/ALM vs *UCMS/ALM). Data represents mean $\pm$ SEM; one symbol $p < 0.05$, two symbols $p < 0.01$, three symbols $p < 0.001$; sample sizes indicated in (a) ($n = 14$ – 19 mice/group) concern all physical and behavioral measures illustrated in this Figure and in Figure 3.

rons), and BrdU/NeuN-labeled (newborn mature neurons) cells in the granular cell layer of the DG. As dorsal and ventral parts of the hippocampus do not share the same connectivity with afferent and efferent areas (Fanselow and Dong, 2010), and as only the ventral part is known to regulate the HPA axis through polysynaptic neuronal circuit towards the PVN (Herman *et al*, 2005; Mizoguchi *et al*, 2003; Ulrich-Lai and Herman, 2009), cell proliferation and neurogenesis were examined separately in the dorsal, intermediate, and ventral parts of the hippocampus (Franklin and Paxinos, 2008). In this study, as results for dorsal and intermediate hippocampus are identical, only comparisons between dorsal and ventral parts are presented here (results for the intermediate part are presented in Supplementary Figure 2). Full explanation of image analyses and cell quantification are available in Supplementary Materials and Methods.

Statistics

Considering that relatively small sample sizes were used ($n \leq 19$ mice per group for behavioral analysis and $n \leq 8$ mice per group for neurobiological analysis) and that assumptions for parametric statistics could not be ensured (normality and homoscedasticity), data were analyzed using the non-parametric Kruskal–Wallis ‘ANOVA by ranks’

H-test. Significant effects (ie, $p < 0.05$) were followed up with *post-hoc* Mann–Whitney *U*-tests with Holm–Bonferroni correction when appropriate (Aickin and Gensler, 1996). The Holm–Bonferroni method was not applied for DEX suppression test analysis due to the small sample size ($n = 5$ mice per group). *p*-Values that are indicated in the Results section always derived from the between-groups comparisons using the Kruskal–Wallis *H*-test, while *p*-values resulting from *post-hoc* comparisons are indicated in the figures. All data are expressed as mean $\pm$ standard error of the mean (SEM), and the sample sizes are provided in the figure legends.

RESULTS

Physical and Behavioral Effects of UCMS and Pharmacological Treatments

We first assessed the effects of chronic administration of ALM and FLX on physical state and behavior in mice subjected to 9-week UCMS or maintained under non-stressful conditions (non-UCMS mice).

UCMS induced a gradual deterioration of the coat state that appeared after 1 week of stress, whereas no degradation was observed in non-UCMS mice (Figure 2a). Interestingly, in contrast to UCMS/VEH mice whose physical state

Figure 3 Effects of the unpredictable chronic mild stress (UCMS) and 7-week treatment with fluoxetine (FLX, 20 mg/kg per day, *per os* (p.o.)) or almorexant (ALM, 100 mg/kg per day, p.o.) on behaviors. (a) The UCMS increased the time of immobility in the tail suspension test (TST) (non-UCMS/vehicle (VEH) group vs UCMS/VEH group), while pharmacological treatments decreased this alteration (UCMS/VEH group vs UCMS/FLX or UCMS/ALM groups). Furthermore, significant difference was also observed between the UCMS/FLX group and [#]UCMS/ALM groups. (b) The UCMS decreased the attack latency in the resident-intruder (R-I) test (non-UCMS/VEH group vs UCMS/VEH group), whereas pharmacological treatments reversed this agonistic behavior (UCMS/VEH group vs UCMS/FLX or UCMS/ALM groups). (c) In the elevated plus maze (EPM), the UCMS decreased the time spent in open arms (non-UCMS/VEH group vs UCMS/VEH group), whereas pharmacological treatments reversed this UCMS-induced effect (UCMS/VEH group vs UCMS/FLX or UCMS/ALM groups). In addition, FLX also increased the time spent in open arms in non-UCMS mice (non-UCMS/FLX group vs [§]non-UCMS/VEH or [§]non-UCMS/ALM groups). (d) The UCMS induced an increase of the latency to eat the pellet in the novelty-suppressed feeding (NSF) test (non-UCMS/VEH group vs UCMS/VEH group), whereas FLX reversed this alteration (UCMS/VEH group vs UCMS/FLX group). However, ALM seemed to increase the latency to eat the pellet (non-UCMS/ALM group vs [§]non-UCMS/VEH or [§]non-UCMS/FLX groups). Data represents mean $\pm$ SEM; * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$; $n = 14$ –19 mice per group as shown in Figure 2.

worsened until the end of the UCMS procedure, chronic administration of FLX and ALM improved coat state reaching significance after 3 weeks of treatment (Figure 2a; full statistic details are provided in Supplementary Table 1). A gradual increase of body weight was observed during the 9 weeks of UCMS (Figure 2b). Although no effect of UCMS or chronic FLX treatment was noticed, chronic ALM administration significantly reduced the weight gain as it can be seen at the end of experimental protocol ($p < 0.001$; Figure 2b), without inducing any significant differences in body weight when compared with corresponding VEH groups (data not shown).

Locomotor activity was neither affected by UCMS or treatments 18 h after the last oral administration (at the time of the behavioral test), nor 10 h after (Figure 2c). Nevertheless, 2 h after administration of treatments, ALM

significantly decreased the locomotor activity of mice in both UCMS and non-UCMS groups ($p < 0.001$; Figure 2c).

UCMS also induced behavioral alterations that were consistently restored after pharmacological treatments (except in the NSF test for ALM-treated mice). Importantly, none of these alterations were due to changes in locomotor activity, as all behavioral tests were carried out at a time point at which no change in locomotion was observed. In the TST, UCMS induced an increase of immobility, an effect counteracted by FLX and ALM treatments in both UCMS and non-UCMS mice ($p < 0.001$; Figure 3a). Furthermore, in the R-I test, a decrease of attack latency was observed in UCMS/VEH mice, reversed by FLX and ALM treatments ($p < 0.001$; Figure 3b). No effect of treatments was observed in non-UCMS mice. Moreover, in the EPM, UCMS reduced the time spent in open arms, an effect reversed by FLX and

Figure 4 Effects of the unpredictable chronic mild stress (UCMS) and 7-week treatment with fluoxetine (FLX, 20 mg/kg per day, *per os* (p.o.)) or almorexant (ALM, 100 mg/kg per day, p.o.) on the dexamethasone (DEX) suppression test. (a) The UCMS induced a decrease of the DEX-induced suppression of plasma corticosterone (CORT) (non-UCMS/vehicle (VEH) group vs UCMS/VEH group), whereas FLX and ALM treatments reversed this alteration (UCMS/VEH group vs § UCMS/FLX or § UCMS/ALM groups). (b) The UCMS also decreased the DEX-induced suppression of Fos-immunoreactive neurons in the parvocellular nuclei of the paraventricular nucleus (PVN) (non-UCMS/VEH group vs UCMS/VEH group), whereas both pharmacological treatments counteracted this alteration (UCMS/VEH group vs § UCMS/FLX or § UCMS/ALM groups). (c) Representative images of single-labeled Fos-immunoreactive neurons (in black) counted in the parvocellular nuclei of the PVN, around the third ventricle (3v), to assess the reactivity of the negative feedback of the hypothalamic-pituitary-adrenal (HPA) axis through the DEX suppression test (magnification bar, 100 μ m). In graphs, 100% value represents a full DEX-induced suppression of plasma corticosterone or Fos expression in the PVN. Data represent mean $\pm$ SEM; one symbol $p < 0.05$, two symbols $p < 0.01$; $n = 5$ mice per group.

ALM treatments, while FLX also increased the time spent in open arms in non-UCMS mice ($p < 0.001$; Figure 3c). Finally, in the NSF test, UCMS increased the latency to eat, an effect restored by FLX ($p < 0.001$; Figure 3d). No effect of FLX was observed in non-UCMS mice. Nevertheless, in the NSF test, ALM did not block the behavioral alteration induced by UCMS, as this treatment significantly increases the latency to eat the pellet in non-UCMS group. However, when returned to their home cage, mice did not display any difference in the latency to smell the pellet or in the food consumption 5 min after the test (data not shown).

Effects of UCMS and Pharmacological Treatments on HPA Axis Negative Feedback

Depressive states are often associated with hyperactivity of HPA axis that can be reversed by antidepressants (Ising *et al*, 2007). We thus examined the integrity of the negative feedback of the HPA axis through the DEX suppression test following UCMS and chronic pharmacological treatments. In this test, the administration of the glucocorticoid receptor agonist DEX-phosphate (0.1 mg/kg, intraperitoneally) is known to decrease the plasma corticosterone level and to attenuate or suppress the activation of the PVN parvocellular nuclei through the activation of the negative feedback when it is undamaged.

We found that UCMS dampened the effectiveness of the negative feedback loop of the HPA axis and this was reversed by the pharmacological treatments. Indeed, the percentage of corticosterone suppression induced by DEX injection was strikingly decreased by UCMS (non-UCMS/VEH mice $\sim 55\%$ vs UCMS/VEH mice $\sim 7\%$), and this effect was reversed after chronic FLX ($\sim 52\%$) and ALM ($\sim 51\%$) treatments ($p < 0.01$; Figure 4a). The percentage of Fos-positive neurons in the PVN was also reduced following

UCMS (non-UCMS/VEH mice $\sim 42\%$ vs UCMS/VEH mice $\sim 6\%$), whereas FLX ($\sim 39\%$) and ALM ($\sim 32\%$) treatments restored the Fos activation of PVN neurons ($p < 0.01$; Figure 4b). Importantly, no significant effect of UCMS or treatments on plasma corticosterone level or Fos expression in the parvocellular nuclei of the PVN in control mice receiving saline solution was noticed (data not shown).

Effects of UCMS and Pharmacological Treatments on Hippocampal Cell Proliferation, Neurogenesis, and Neuronal Survival

Antidepressant drugs require or modulate hippocampal cell proliferation or neurogenesis (Santarelli *et al*, 2003; Surget *et al*, 2008, 2011). We therefore studied the ability of chronically administrated ALM and FLX to modulate hippocampal cell proliferation and neurogenesis in UCMS- and non-UCMS-subjected mice.

For this purpose, we first assessed UCMS and treatment effects on hippocampal cell proliferation using Ki-67 marker. We observed that UCMS induced a decrease of Ki-67-positive cell density in the dorsal hippocampus ($\sim -46\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5a), and a greater decrease in the ventral part of hippocampus ($\sim -63\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5a). These reductions were reversed by FLX in both parts of the DG. UCMS/FLX mice exhibited a significantly higher Ki-67-positive cell density than in non-UCMS/FLX group, with no effect of FLX in the non-UCMS group, suggesting that FLX increased cell proliferation only in stressed mice. Interestingly, Ki-67-positive cell density was not increased in either parts of the hippocampus following chronic ALM in UCMS mice and was decreased in the ventral hippocampus of non-UCMS animals following chronic ALM treatment.

Figure 5 Effects of the unpredictable chronic mild stress (UCMS) and 7-week treatment with fluoxetine (FLX, 20 mg/kg per day, *per os* (p.o.)) or almorexant (ALM, 100 mg/kg per day, p.o.) on the cell proliferation, neurogenesis and neuronal survival in the dorsal and the ventral hippocampus. (a) The cell proliferation was assessed by the number of Ki-67-positive cells per mm³ of the granule cell layer (GCL). In the dorsal hippocampus, the UCMS induced a significant decrease of cell proliferation (Non-UCMS/vehicle (VEH) group vs UCMS/VEH group), reversed by FLX (UCMS/VEH vs UCMS/FLX group) but not by ALM (UCMS/FLX group vs UCMS/ALM group). Significant differences were also observed between the non-UCMS/FLX group vs [§]UCMS/FLX group, and between the non-UCMS/ALM group and [#]UCMS/ALM group). In the ventral hippocampus, the UCMS also decreased the cell proliferation (non-UCMS/VEH group vs UCMS/VEH groups), whereas FLX treatment reversed this alteration (UCMS/VEH group vs UCMS/FLX groups) without any effect of ALM (UCMS/FLX vs UCMS/ALM groups). FLX treatment exhibited an effect only in UCMS-subjected animals (non-UCMS/FLX group vs [§]UCMS/FLX groups). Furthermore, ALM treatment reduced the ventral hippocampal cell proliferation (non-UCMS/VEH or non-UCMS/FLX groups vs non-UCMS/ALM group). (b) The generation of immature neurons was assessed by the number of doublecortin (DCX)-positive cells per mm³ of the granule cell layer (GCL). In the dorsal part of hippocampus, the UCMS induced a decrease of immature neurons genesis (non-UCMS/VEH group vs UCMS/VEH group), while treatment with FLX counteracted this reduction (UCMS/VEH group vs UCMS/FLX group). No effect of ALM was noticed in stressed mice (UCMS/FLX group vs UCMS/ALM group). A significant difference was also observed between the non-UCMS/ALM group and [§]UCMS/ALM group. In the ventral hippocampus, the UCMS decreased the immature neurons immunoreactivity (non-UCMS/VEH group vs UCMS/VEH group), which was reversed by FLX (UCMS/VEH group vs UCMS/FLX). Concerning ALM treatment, in addition to the absence of treatment effect in the UCMS group (UCMS/FLX group vs UCMS/ALM group), the orexinergic antagonist decreased ventral hippocampal neurogenesis in non-UCMS mice (non-UCMS/VEH group or non-UCMS/FLX group vs non-UCMS/ALM group). (c) The density of mature neurons (4 weeks old) was assessed by the number of NeuN-positive cells expressing 5-bromo-2'-deoxyuridine (BrdU) marker per mm³ in the (GCL). In the dorsal hippocampus, the UCMS decreased the density of mature neurons (non-UCMS/VEH group vs UCMS/VEH group), whereas FLX treatment reversed this alteration (UCMS/VEH group vs UCMS/FLX group). Although no effect of ALM was observed (UCMS/FLX group vs UCMS/ALM group), FLX increased the proportion of mature neurons in non-UCMS mice (non-UCMS/FLX group vs non-UCMS/VEH or non-UCMS/ALM groups, and non-UCMS/FLX group vs [§]UCMS/FLX group). A significant difference was also observed between non-UCMS/ALM group and [#]UCMS/ALM group. In the ventral part of hippocampus, a UCMS-induced decrease of the density of mature neurons was noticed (non-UCMS/VEH group vs UCMS/VEH group), reversed by FLX (UCMS/VEH group vs UCMS/FLX group) but not by ALM (UCMS/FLX group vs UCMS/ALM group). Furthermore, the treatment with ALM decreased the neurogenesis in the ventral hippocampus (non-UCMS/VEH group vs non-UCMS/ALM group), where as the UCMS further reduced the number of mature neurons (non-UCMS/ALM group vs [#]UCMS/ALM group). FLX treatment also increased neurogenesis in non-UCMS mice (non-UCMS/FLX group vs non-UCMS/VEH or non-UCMS/ALM groups, and non-UCMS/FLX group vs [§]UCMS/FLX group). Data represent mean $\pm$ SEM; * $p < 0.05$, ** $p < 0.01$; $n = 8$ mice/group.

We then focused on the newborn immature neurons by assessing the density of DCX-expressing cells in the DG. We found that UCMS decreased hippocampal DCX-positive cell density in the dorsal hippocampus ($\sim -35\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5b), and even more in the ventral hippocampus ($\sim -56\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5b). FLX treatment significantly reversed this disruption, whereas no change of DCX-positive cell density was seen in ALM-treated UCMS mice in both parts of the hippocampus. Furthermore, in the ventral hippocampus, non-UCMS mice chronically treated with ALM exhibited a decrease of DCX-positive cell density.

Finally, we examined the survival of adult newborn neurons through double-labeled cells with the neuronal marker NeuN and the cellular division marker BrdU (injected 4 weeks before animals sacrifice). We observed a UCMS-

mediated decrease in hippocampal BrdU/NeuN-positive cell density in the dorsal ($\sim -73\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5c) and particularly in the ventral part of hippocampus ($\sim -86\%$, non-UCMS/VEH vs UCMS/VEH, $p < 0.001$; Figure 5c), an effect again reversed by FLX, but not by ALM. The latter also decreased the density of BrdU/NeuN-positive neurons in the ventral hippocampus in non-UCMS mice. In addition, we found that in non-UCMS mice, FLX significantly increased the proportion of mature neurons in dorsal and ventral hippocampus compared with other non-stressed animals.

To summarize, chronic ALM treatment was unable to counteract the UCMS effects on cell proliferation, neurogenesis, and neuronal survival in the entire DG, and even decreased it in the ventral hippocampus of non-stressed animals.

DISCUSSION

Since the first studies reporting on the putative link between orexins and MD, there has been little progress in understanding the importance of such neuropeptidergic system in depressive-like and anxiety states. Indeed, preclinical and clinical studies dealing with the involvement of the orexinergic system in the onset of depressive symptoms led to conflicting results, ranging from a hypoactivity (Allard *et al*, 2004; Brundin *et al*, 2007a; Ito *et al*, 2008; Lutter *et al*, 2008; Taheri *et al*, 2001) or hyperactivity (Feng *et al*, 2007, 2008; Mikrouli *et al*, 2011; Salomon *et al*, 2003; von der Goltz *et al*, 2011) of orexinergic signaling. It has also been shown that intracerebroventricular administration or amygdala infusion of OX-A induces anxiety behaviors (Avolio *et al*, 2011; Suzuki *et al*, 2005). Furthermore, Johnson *et al* (2010) demonstrated that orexin neurons, especially in the DMH-PFA, are necessary for the occurrence of anxiety-like behavior in panic-prone rats since silencing hypothalamic OX gene or intraperitoneal pretreatment with OXR1 antagonists blocks the panic responses. In line with the latter results, we recently reported that UCMS-subjected mice exhibited an increase of neuronal activation in the DMH-PFA orexinergic neurons compared with LH orexinergic neurons and that this effect was reversed by chronic FLX treatment (Nollet *et al*, 2011).

To the best of our knowledge, this study is the first to demonstrate a clear involvement of orexin signaling in a depressive-like state. One of our meaningful outcomes is the robust physical and behavioral antidepressant-like effects of the dual orexin receptor antagonist ALM. The UCMS procedure induced a depressive-like state in mice regarding their physical condition, with a clear deterioration of coat state that was reversed, as described previously, by chronic FLX treatment (Nollet *et al*, 2011; Santarelli *et al*, 2003; Surget *et al*, 2008, 2009), and more interestingly by chronic treatment with ALM. In addition, we found a regular increase of body weight during the entire protocol, while chronic ALM administration slackened the weight gain (without any significant differences in body weight when compared with corresponding VEH-treated groups). This reduction in weight growth could correspond to the decrease of food intake following the blockade of orexinergic system, as orexins are known to be involved in food-seeking (Cason *et al*, 2010; Thompson and Borgland, 2011). The behavioral data demonstrate that the UCMS regimen increased aggressiveness in the R-I test, despair behavior in the TST, and anxiety in the EPM and the NSF test. These behavioral changes were completely reversed by chronic treatment with FLX as demonstrated previously (Kurt *et al*, 2000; Nollet *et al*, 2011; Surget *et al*, 2008, 2009). ALM also reversed all the UCMS-induced behavioral changes besides the NSF test. In the latter behavioral test, the high latency to eat the pellet could reflect a reduced motivation to eat related to the anorexigenic effect of chronic antagonist injection. It is interesting to note that calorie restriction (corresponding to a 20–25% weight loss) is able to induce antidepressant-like effects (Lutter *et al*, 2008). Here, chronic ALM treatment did not induce weight loss but only a slight reduction of body weight gain, suggesting that antidepressant-like effects of ALM seen in our behavioral tests could not be attributed to calorie

restriction or body weight loss. In addition, the ability of NSF test to reveal antidepressant-like effects can be influenced by the presence of hippocampal neurogenesis (David *et al*, 2009), which is highly reduced in our ALM-treated mice. Finally, in accordance with previous studies, chronic FLX and ALM treatments exerted an effect in non-UCMS animals in the TST (Kulkarni and Dhir, 2007; Nollet *et al*, 2011).

Since the restoration of the stress-induced HPA axis dysregulation is linked to the beneficial effects of antidepressant, we therefore assessed the effect of chronic ALM treatment on the putative UCMS-induced disruption of the HPA axis negative feedback loop through the DEX suppression test. Our findings show that chronic stress induced a dysregulation of HPA axis through the decrease of the response following the DEX suppression test. Indeed, both plasma corticosterone levels after DEX injection and Fos expression in parvocellular neurons of the PVN indicated a strong decrease of the negative feedback regulation of the HPA axis after UCMS. This negative feedback control was restored after FLX or ALM chronic treatments, suggesting that antidepressant effects obtained after both treatments could be linked to the restoration of a normal and functional negative feedback loop on HPA axis. These results corroborate the fact that, in most depressed patients with altered HPA axis negative feedback, remission and decreased risk of relapse are associated with the improvement of HPA axis functioning (Appelhof *et al*, 2006; Ising *et al*, 2007; Kunugi *et al*, 2006). Here, we have demonstrated that ALM restored the UCMS-induced HPA negative feedback disruption, sustaining the interaction between the PVN and the orexinergic neuronal population. Indeed, orexin neurons send direct projections to the PVN, particularly to the parvocellular cells (Yoshida *et al*, 2006), while neurons from the PVN innervate orexinergic neurons that express CRH1 and CRH2 receptors (Winsky-Sommerer *et al*, 2004). Moreover, OXR2 is abundant in the PVN (Marcus *et al*, 2001; Trivedi *et al*, 1998), and it has been shown that intracerebroventricular injection of selective OXR2 antagonist attenuates OX-A-induced increase of adrenocorticotrophic hormone levels in rats (Chang *et al*, 2007). Consequently, the mechanism through which ALM restored the negative feedback on the HPA axis could be mediated by neurons located in the PVN through their orexin receptors 2.

In this study, we found that chronic stress suppressed cell proliferation (Ki-67-expressing cells) and neurogenesis (DCX- and BrdU/NeuN-labeled cells) in the hippocampus, confirming previous reports (Czeh *et al*, 2001; Mineur *et al*, 2007; Pham *et al*, 2003). Furthermore, these suppressions affected more specifically the ventral part of the hippocampus, which strengthen evidences linking this region to stress and emotions (Fanselow and Dong, 2010). In accordance with what has been shown formerly, chronic FLX treatment reversed the UCMS-induced hippocampal cell proliferation and neurogenesis suppression (Malberg and Duman, 2003; Santarelli *et al*, 2003; Surget *et al*, 2008, 2011). Moreover, while no effect of FLX was observed in non-stressed mice regarding cell expressing immature neuronal marker DCX, these non-stressed animals treated with FLX exhibited a significant increase of mature neurons (4 weeks old) stained with BrdU/NeuN markers. This

suggests that FLX treatment is able to increase survival or accelerate the maturation of new neurons in non-stressed animals (Perera *et al*, 2011; Wang *et al*, 2008), without increasing cell proliferation (Ki-67-labeled cells) or immature neurons density (DCX-expressing cells).

In our study, chronic treatment with the dual orexin receptor antagonist ALM neither did increase hippocampal cell proliferation nor neurogenesis. This result could be linked to the fact that, on the opposite, OX-A infusion increases cell proliferation (probably through the release of the neuropeptide Y) without affecting the percentage of DCX-positive cells (Ito *et al*, 2008). This is critical as it has been shown that hippocampal neurogenesis is not required for the reversal of the behavioral and physical disruptions of UCMS by compounds targeting directly HPA stress axis response (CRH1 or V1b antagonists) (Surget *et al*, 2008). Moreover, MCH receptor 1 antagonist induces anxiolytic effect independently of hippocampal neurogenesis (David *et al*, 2007). Intriguingly, the blockade of orexinergic system even reduced cell proliferation and neurogenesis specifically in the ventral part of the hippocampus, without inducing depressive-like states *per se*, in line with several (but not all; Snyder *et al*, 2011) studies where no induced-depressive-like phenotypes have been observed in hippocampal neurogenesis-ablated mice (Santarelli *et al*, 2003; Surget *et al*, 2008, 2011). Considering that the ventral hippocampus is more related to emotional states and stress responses than its dorsal part, this result reinforces the idea that orexins play a central role in regulating emotional states and psychological stress (Furlong *et al*, 2009). Nevertheless, additional investigations will be necessary to fully understand this process.

Despite these new outcomes linking orexins and MD, several points need to be clarified by further studies. Here, the antidepressant-like effect underpinned by orexinergic system was obtained by blocking both orexin receptors, while a differential role of orexin receptors in depressive-like behavior has been underlined recently (Scott *et al*, 2011). Furthermore, although our findings suggest that ALM mostly induced an antidepressant-like effect by blocking orexinergic signaling on HPA axis, the therapeutic effect of orexinergic antagonist might also be the result of changes in sleep architecture (Li and Nattie, 2010) or interactions with serotonergic system (Brown *et al*, 2001; Muraki *et al*, 2004). Finally, if our results are in line with previous studies showing a higher release of orexins as well as an increase of the number and activation of orexin neurons in several animal models of MD (Feng *et al*, 2007, 2008; Mikrouli *et al*, 2011; Nollet *et al*, 2011), they partially contradict other preclinical data in which genetic animal model of MD, chronic stress, or social defeat are associated with a decrease of orexinergic immunoreactivity and expression (Allard *et al*, 2004; Ito *et al*, 2009; Lutter *et al*, 2008; Taheri *et al*, 2001). The same discrepancies are observed in clinical studies in which depressive state have been linked to a decrease (Brundin *et al*, 2007a, 2007b, 2009; Rotter *et al*, 2011) or an increase (Palhagen *et al*, 2010; Salomon *et al*, 2003; von der Goltz *et al*, 2011) of OX-A level in cerebrospinal fluid or blood. It should also be noted that narcoleptic patients, characterized by low orexin levels, seem to present a higher rate of depression and anxiety (Dimitrova *et al*, 2011).

Taken together, our findings open new perspectives regarding the implication of the orexinergic system in MD. The fact that the dual orexin receptor antagonist ALM reinstates glucocorticoid feedback inhibition likely through the direct modulation of the PVN, the main central regulator of the stress axis, independently to the restoration of the hippocampal cell proliferation and neurogenesis strongly suggests that orexinergic system plays a significant role in depressive disorders, and underline the non-crucial role of hippocampal neurogenesis in the pathophysiology of MD.

ACKNOWLEDGEMENTS

We thank Dr François Jenck (Actelion Pharmaceuticals) and Actelion Pharmaceuticals for the gift of almorexant, Dr Petra S van Nieuwenhuijzen (University of Sydney) for thoughtful comments on this article, as well as Anne-Marie Le Guisquet, Séverine Devers, Maryse Pingaud, Bruno Brizard, Lucette Garreau, Zuhail Gulhan, Jade Ezzedine, and Teddy Delavallée for assistance.

DISCLOSURE

The authors declare no conflict of interest.

REFERENCES

- Aickin M, Gensler H (1996). Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. *Am J Public Health* **86**: 726–728.
- Airan RD, Meltzer LA, Roy M, Gong Y, Chen H, Deisseroth K (2007). High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. *Science* **317**: 819–823.
- Allard JS, Tizabi Y, Shaffery JP, Trough CO, Manaye K (2004). Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. *Neuropeptides* **38**: 311–315.
- Alonso R, Griebel G, Pavone G, Stemmelin J, le Fur G, Soubrie P (2004). Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. *Mol Psychiatry* **9**: 278–286, 224.
- Appelhof BC, Huyser J, Verweij M, Brouwer JP, van Dyck R, Fliers E *et al* (2006). Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). *Biol Psychiatry* **59**: 696–701.
- Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P *et al* (2010). Lateral hypothalamic orexin/hypocretin neurons: a role in reward-seeking and addiction. *Brain Res* **1314**: 74–90.
- Avolio E, Alo R, Carelli A, Canonaco M (2011). Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. *Behav Brain Res* **218**: 288–295.
- Brisbare-Roch C, Dingemans J, Koberstein R, Hoeve P, Aissaoui H, Flores S *et al* (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nat Med* **13**: 150–155.
- Brown RE, Sergeeva O, Eriksson KS, Haas HL (2001). Orexin A excites serotonergic neurons in the dorsal raphe nucleus of the rat. *Neuropharmacology* **40**: 457–459.
- Brundin L, Bjorkqvist M, Petersen A, Traskman-Bendz L (2007a). Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. *Eur Neuropsychopharmacol* **17**: 573–579.

- Brundin L, Bjorkqvist M, Traskman-Bendz L, Petersen A (2009). Increased orexin levels in the cerebrospinal fluid the first year after a suicide attempt. *J Affect Disord* 113: 179–182.
- Brundin L, Petersen A, Bjorkqvist M, Traskman-Bendz L (2007b). Orexin and psychiatric symptoms in suicide attempters. *J Affect Disord* 100: 259–263.
- Cao M, Guilleminault C (2011). Hypocretin and its emerging role as a target for treatment of sleep disorders. *Curr Neurol Neurosci Rep* 11: 227–234.
- Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, Aston-Jones G (2010). Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. *Physiol Behav* 100: 419–428.
- Chang H, Saito T, Ohiwa N, Tateoka M, Deocaris CC, Fujikawa T *et al* (2007). Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats. *Neurosci Res* 57: 462–466.
- Cryan JF, Holmes A (2005). The ascent of mouse: advances in modelling human depression and anxiety. *Nat Rev Drug Discov* 4: 775–790.
- Czéh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M *et al* (2001). Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. *Proc Natl Acad Sci USA* 98: 12796–12801.
- David DJ, Klemm Hagen KC, Holick KA, Saxe MD, Mendez I, Santarelli L *et al* (2007). Efficacy of the MCHR1 antagonist N-[3-(1-{4-(3,4-difluorophenoxy)phenyl}methyl)(4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. *J Pharmacol Exp Ther* 321: 237–248.
- David DJ, Samuels BA, Rainer Q, Wang JW, Marsteller D, Mendez I *et al* (2009). Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. *Neuron* 62: 479–493.
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE *et al* (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci USA* 95: 322–327.
- Dimitrova A, Fronczek R, Van der Ploeg J, Scammell T, Gautam S, Pascual-Leone A *et al* (2011). Reward-seeking behavior in human narcolepsy. *J Clin Sleep Med* 7: 293–300.
- El Hage W, Powell JF, Surguladze SA (2009). Vulnerability to depression: what is the role of stress genes in gene $\times$ environment interaction? *Psychol Med* 39: 1407–1411.
- Fanselow MS, Dong HW (2010). Are the dorsal and ventral hippocampus functionally distinct structures? *Neuron* 65: 7–19.
- Feng P, Vurbic D, Wu Z, Hu Y, Strohl KP (2008). Changes in brain orexin levels in a rat model of depression induced by neonatal administration of clomipramine. *J Psychopharmacol* 22: 784–791.
- Feng P, Vurbic D, Wu Z, Strohl KP (2007). Brain orexins and wake regulation in rats exposed to maternal deprivation. *Brain Res* 1154: 163–172.
- Franklin KBJ, Paxinos G (2008). *The Mouse Brain in Stereotaxic Coordinates* 3rd edn Academic Press, Elsevier: New York.
- Furlong TM, Vianna DM, Liu L, Carrive P (2009). Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. *Eur J Neurosci* 30: 1603–1614.
- Harris GC, Wimmer M, Aston-Jones G (2005). A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437: 556–559.
- Herman JP, Ostrander MM, Mueller NK, Figueiredo H (2005). Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. *Prog Neuropsychopharmacol Biol Psychiatry* 29: 1201–1213.
- Ising M, Horstmann S, Kloiber S, Lucae S, Binder EB, Kern N *et al* (2007). Combined dexamethasone/corticotropin releasing hormone test predicts treatment response in major depression—a potential biomarker? *Biol Psychiatry* 62: 47–54.
- Ito N, Yabe T, Gamo Y, Nagai T, Oikawa T, Yamada H *et al* (2008). I.c.v. administration of orexin-A induces an antidepressant-like effect through hippocampal cell proliferation. *Neuroscience* 157: 720–732.
- Ito N, Yabe T, Nagai T, Oikawa T, Yamada H, Hanawa T (2009). A possible mechanism underlying an antidepressant-like effect of Kososan, a Kampo medicine, via the hypothalamic orexinergic system in the stress-induced depression-like model mice. *Biol Pharm Bull* 32: 1716–1722.
- Jiang W, Zhang Y, Xiao L, van Cleemput J, Ji SP, Bai G *et al* (2005). Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. *J Clin Invest* 115: 3104–3116.
- Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S *et al* (2010). A key role for orexin in panic anxiety. *Nat Med* 16: 111–115.
- Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR *et al* (2009). Amyloid-beta dynamics are regulated by orexin and the sleep–wake cycle. *Science* 326: 1005–1007.
- Keller MC, Neale MC, Kendler KS (2007). Association of different adverse life events with distinct patterns of depressive symptoms. *Am J Psychiatry* 164: 1521–1529.
- Kulkarni SK, Dhir A (2007). Effect of various classes of antidepressants in behavioral paradigms of despair. *Prog Neuropsychopharmacol Biol Psychiatry* 31: 1248–1254.
- Kunugi H, Ida I, Ohashi T, Kimura M, Inoue Y, Nakagawa S *et al* (2006). Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study. *Neuropsychopharmacology* 31: 212–220.
- Kurt M, Arik AC, Celik S (2000). The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. *J Basic Clin Physiol Pharmacol* 11: 173–180.
- Li A, Nattie E (2010). Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. *J Physiol* 588: 2935–2944.
- Lopez M, Tena-Sempere M, Dieguez C (2010). Cross-talk between orexins (hypocretins) and the neuroendocrine axes (hypothalamic-pituitary axes). *Front Neuroendocrinol* 31: 113–127.
- Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, Nestler EJ (2008). Orexin signaling mediates the antidepressant-like effect of calorie restriction. *J Neurosci* 28: 3071–3075.
- Malberg JE, Duman RS (2003). Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. *Neuropsychopharmacology* 28: 1562–1571.
- Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. *J Neurosci* 20: 9104–9110.
- Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M *et al* (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* 435: 6–25.
- McEwen BS, Magarinos AM, Reagan LP (2002). Structural plasticity and tianeptine: cellular and molecular targets. *Eur Psychiatry* 17(Suppl 3): 318–330.
- Mikrouli E, Wortwein G, Soylu R, Mathe AA, Petersen S (2011). Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. *Neuropeptides* 45: 401–406.
- Mineur YS, Belzung C, Crusio WE (2007). Functional implications of decreases in neurogenesis following chronic mild stress in mice. *Neuroscience* 150: 251–259.

- Mineur YS, Prasol DJ, Belzung C, Crusio WE (2003). Agonistic behavior and unpredictable chronic mild stress in mice. *Behav Genet* 33: 513–519.
- Mizoguchi K, Ishige A, Aburada M, Tabira T (2003). Chronic stress attenuates glucocorticoid negative feedback: involvement of the prefrontal cortex and hippocampus. *Neuroscience* 119: 887–897.
- Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T (2004). Serotonergic regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. *J Neurosci* 24: 7159–7166.
- Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002). Neurobiology of depression. *Neuron* 34: 13–25.
- Noll M, Gaillard P, Minier F, Tanti A, Belzung C, Leman S (2011). Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression. *Neuropharmacology* 61: 336–346.
- Palhagen S, Qi H, Martensson B, Walinder J, Granerus AK, Svenningsson P (2010). Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. *J Neurol* 257: 524–532.
- Perera TD, Dwork AJ, Keegan KA, Thirumangalakudi L, Lipira CM, Joyce N *et al* (2011). Necessity of hippocampal neurogenesis for the therapeutic action of antidepressants in adult nonhuman primates. *PLoS One* 6: e17600.
- Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG *et al* (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18: 9996–10015.
- Pham K, Nacher J, Hof PR, McEwen BS (2003). Repeated restraint stress suppresses neurogenesis and induces biphasic PSA-NCAM expression in the adult rat dentate gyrus. *Eur J Neurosci* 17: 879–886.
- Revesz D, Tjernstrom M, Ben-Menachem E, Thorlin T (2008). Effects of vagus nerve stimulation on rat hippocampal progenitor proliferation. *Exp Neurol* 214: 259–265.
- Rotter A, Asemann R, Decker A, Kornhuber J, Biermann T (2011). Orexin expression and promoter-methylation in peripheral blood of patients suffering from major depressive disorder. *J Affect Disord* 131: 186–192.
- Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H *et al* (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.
- Sakurai T, Mieda M, Tsujino N (2010). The orexin system: roles in sleep/wake regulation. *Ann NY Acad Sci* 1200: 149–161.
- Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM *et al* (2003). Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. *Biol Psychiatry* 54: 96–104.
- Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S *et al* (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. *Science* 301: 805–809.
- Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE *et al* (2011). Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. *Behav Brain Res* 222: 289–294.
- Sibille E, Wang Y, Joeyen-Waldorf J, Gaiteri C, Surget A, Oh S *et al* (2009). A molecular signature of depression in the amygdala. *Am J Psychiatry* 166: 1011–1024.
- Snyder JS, Soumier A, Brewer M, Pickel J, Cameron HA (2011). Adult hippocampal neurogenesis buffers stress responses and depressive behaviour. *Nature* 476: 458–461.
- Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG (2006). Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. *Pharmacol Rev* 58: 46–57.
- Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. *Psychopharmacology (Berl)* 85: 367–370.
- Surget A, Saxe M, Leman S, Ibarguen-Vargas Y, Chalon S, Griebel G *et al* (2008). Drug-dependent requirement of hippocampal neurogenesis in a model of depression and of antidepressant reversal. *Biol Psychiatry* 64: 293–301.
- Surget A, Tanti A, Leonardo ED, Laugeray A, Rainer Q, Touma C *et al* (2011). Antidepressants recruit new neurons to improve stress response regulation. *Mol Psychiatry* 16: 1177–1188.
- Surget A, Wang Y, Leman S, Ibarguen-Vargas Y, Edgar N, Griebel G *et al* (2009). Corticolimbic transcriptome changes are state-dependent and region-specific in a rodent model of depression and of antidepressant reversal. *Neuropsychopharmacology* 34: 1363–1380.
- Suzuki M, Beuckmann CT, Shikata K, Ogura H, Sawai T (2005). Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. *Brain Res* 1044: 116–121.
- Taheri S, Gardiner J, Hafizi S, Murphy K, Dakin C, Seal L *et al* (2001). Orexin A immunoreactivity and preproorexin mRNA in the brain of Zucker and WKY rats. *NeuroReport* 12: 459–464.
- Tanti A, Belzung C (2010). Open questions in current models of antidepressant action. *Br J Pharmacol* 159: 1187–1200.
- Thompson JL, Borgland SL (2011). A role for hypocretin/orexin in motivation. *Behav Brain Res* 217: 446–453.
- Trivedi P, Yu H, MacNeil DJ, van der Ploeg LH, Guan XM (1998). Distribution of orexin receptor mRNA in the rat brain. *FEBS Lett* 438: 71–75.
- Ulrich-Lai YM, Herman JP (2009). Neural regulation of endocrine and autonomic stress responses. *Nat Rev Neurosci* 10: 397–409.
- von der Goltz C, Koopmann A, Dinter C, Richter A, Grosshans M, Fink T *et al* (2011). Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. *Horm Behav* 60: 644–650.
- Wang JW, David DJ, Monckton JE, Battaglia F, Hen R (2008). Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. *J Neurosci* 28: 1374–1384.
- Willner P (1997). Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. *Psychopharmacology (Berl)* 134: 319–329.
- Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, Sakurai T *et al* (2004). Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. *J Neurosci* 24: 11439–11448.
- Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE (2006). Afferents to the orexin neurons of the rat brain. *J Comp Neurol* 494: 845–861.
- Yoshimizu T, Chaki S (2004). Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. *Biochem Biophys Res Commun* 315: 493–496.

Supplementary Information accompanies the paper on the Neuropsychopharmacology website (<http://www.nature.com/npp>)